Clinical implications and management of drug-drug interactions between antiretroviral agents and psychotropic medications

Authors:
  • MJMeredith G. Jernigan
    Meredith G. Jernigan
  • GKGretchen M. Kipp
    Gretchen M. Kipp
  • ARAshley Rather
    Ashley Rather
  • MJMatthew T. Jenkins
    Matthew T. Jenkins
  • ACAllison M. Chung
    Allison M. Chung

Abstract
Medications used in the treatment of human immunodeficiency virus (HIV) often have drug-drug interactions which complicate treatment of psychiatric illnesses in HIV-infected patients. Protease inhibitors (PIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs) are the two classes of HIV medications most likely to be involved with interactions, with the majority occurring via the cytochrome P450 (CYP450) system. These interactions can result in either increased or decreased exposure to psychotropic and antiretroviral medications, often requiring dosage adjustments and increased monitoring. This article reviews some of the major drug interactions with antiretroviral agents.

This publication has 61 references indexed in Scilit: